Clinical Epidemiology and Ageing

Prevalence and predictive value of pre-therapeutic sarcopenia in cancer patients: A systematic review.

Pamoukdjian F, Bouillet T, Lévy V, Soussan M, Zelek L, Paillaud E Clin Nutr. 2018;37(4):1101-1113.

<p><b>BACKGROUND & AIMS: </b>To assess the prevalence of sarcopenia before cancer treatment and its predictive value during the treatment.</p><p><b>METHODS: </b>We searched MEDLINE via PubMed for articles published from 2008 to 2016 that reported prospective observational or interventional studies of the prevalence of pre-therapeutic sarcopenia and its consequences in adults with cancer who were 18 years or older. Two independent reviewers selected articles based on titles and/or abstracts before a complete review. Sarcopenia had to be measured before cancer treatment. Methods recommended by consensuses (CT scan, MRI, dual X-ray absorptiometry or bio-impedancemetry) to assess sarcopenia were considered. Characteristics of the studies included the prevalence of pre-therapeutic sarcopenia and the prognostic value for outcomes during the cancer treatment.</p><p><b>RESULTS: </b>We selected 35 articles involving 6894 participants (in/out patients, clinical trials). The mean age ranged from 53 to 69.6 years. Pre-therapeutic sarcopenia was found in 38.6% of patients [95% CI 37.4-39.8]. Oesophageal and small-cell lung cancers showed the highest prevalence of pre-therapeutic sarcopenia. Pre-therapeutic sarcopenia was significantly and independently associated with post-operative complications, chemotherapy-induced toxicity and poor survival in cancer patients.</p><p><b>CONCLUSIONS: </b>Pre-therapeutic sarcopenia is highly prevalent in cancer patients and has severe consequences for outcomes of cancer patients.</p>

DOI: 10.1016/j.clnu.2017.07.010

Ajouter un commentaire

3 + 10 =